DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarketsDUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets

Understanding Active Pharmaceutical Ingredients (APIs): Online Training Course (Apr 29-30, 2026) – Enhance Your API Expertise with In-Depth GMP and GDP Training – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

An active pharmaceutical ingredient (API) or drug substance is any substance or mixture of substances intended to be used in the manufacture of a medicinal product, which is intended to furnish pharmacological activity, or have another direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or affect the structure and function of the body.

This course has been designed to provide attendees with a fundamental understanding of best practice and the regulatory environment applicable to active pharmaceutical ingredients in the pharmaceutical industry. It will cover key terminology, the EU and USA regulatory framework, Good Manufacturing Practice (GMP) requirements including controls and validation, and consider Good Distribution Practice (GDP) and how to manage your supply chain. Practical exercises will form part of the course to aid the learning process.

This is an essential and valuable introduction to the manufacture of APIs.

Benefits of Attending:

  • Gain a comprehensive overview of the API regulatory framework
  • Enhance your understanding of the key terms used in API manufacture
  • Recognise how Good Manufacturing Practices (GMP) apply to API synthesis
  • Understand the different approaches between small-molecule and large molecule processing
  • Learn how to manage the risk associated with your supply chain

Who Should Attend:

  • New entrants to those individuals working in a GxP environment
  • Quality management manufacturing specialists
  • Regulatory compliance specialists
  • Pharmaceutical technical professionals
  • Pharmaceutical professionals looking to enhance their Continuous Professional Development (CPD)

Agenda: Day 1

Introduction to APIs

  • Terminology and acronyms
  • Globalisation
  • Introduction to the regulatory framework

Methods and equipment – Part 1

  • Chemical synthesis
  • Reactors
  • Isolation
  • Drying
  • Exercise: managing particle size

Methods and equipment – Part 2

  • Biological
  • Fermentation
  • Harvesting
  • Exercise: impurities

Good Manufacturing Practice (GMP)

  • Requirements
  • Regulations
  • EU
  • FDA
  • Exercise: similarities and differences

GMP requirements (continued)

  • Pharmaceutical Quality System
  • Validation and Qualification
  • Outsourcing
  • Exercise: specialist or generalist

Supply chain considerations

  • Falsified Medicines Directive (FMD)
  • Good Distribution Practice (GDP) for APIs
  • Exercise risk mitigation

Agenda: Day 2

Introduction and recap

Registration aspects of production and control

  • The registration process
  • The Common Technical Document (CTD)
  • Active substance/drug master files
  • Exercise: strategy

Laboratory controls

  • Good Quality Control Laboratory Practice (GQCLP)
  • Validation
  • Stability
  • Exercise: data Integrity

Process validation

  • Purpose of validation
  • General considerations
  • Exercise: critical attributes

Cleaning validation

  • Cleaning strategy
  • Key requirements
  • Residues
  • Exercise: purpose

API control packaging materials

  • What to consider
  • Data requirements
  • Extraction, interaction, migration and sorption
  • Toxicology
  • Exercise: environmental factors

Wrap up and Q&A

For more information about this training visit https://www.researchandmarkets.com/r/ydcok1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
aPriori Logo
aPriori Price(APR)
$0.09488
$0.09488$0.09488
-6.18%
USD
aPriori (APR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Nvidia Partners with Former Crypto Miner Nscale for UK AI Infrastructure Project

Nvidia Partners with Former Crypto Miner Nscale for UK AI Infrastructure Project

TLDR Nvidia announced a $683 million investment in Nscale, a UK AI infrastructure company that spun off from crypto miner Arkon Energy in May 2024 The partnership aims to scale the UK’s AI capacity to 60,000 GPUs by 2026 as part of the government’s national AI infrastructure push Nscale is part of the “neocloud” industry [...] The post Nvidia Partners with Former Crypto Miner Nscale for UK AI Infrastructure Project appeared first on CoinCentral.
Share
Coincentral2025/09/18 16:24
XRP’s Biggest Drawback Uncovered by Top Analyst, It Is Not Price

XRP’s Biggest Drawback Uncovered by Top Analyst, It Is Not Price

The post XRP’s Biggest Drawback Uncovered by Top Analyst, It Is Not Price appeared on BitcoinEthereumNews.com. XRP, within the week, dipped below the psychological $3 level again and shed 6.21% in the last seven days. This long, drawn-out consolidation has raised concerns among XRP investors. Versan Aljarrah, the founder of Black Swan Capitalist, has shared new insights into the seeming stagnation in the price of the asset. XRP price suppression strategy Aljarrah claims that the low price of XRP is not a weakness in the momentum of the asset. Rather, it is due to major institutions intentionally suppressing it for their own interest. According to him, these powerful traditional institutions are looking to stockpile XRP at this low price, hence the deliberate suppression. We agree, #XRP isn’t stuck, it’s being stalled, the strategic value alone confirms it, If the dollar is overextended and liquidity is strained as a result, XRP is the alternative source and bridge that provides liquidity for institutions, Thats how it becomes the solution. https://t.co/ZadNEIUhhk — Black Swan Capitalist (@VersanAljarrah) September 19, 2025 Aljarrah appears aligned with the views of Jim Willie, who alleged that big banks, including BlackRock, the asset manager, are actively accumulating the asset to have leverage when the price soars to over $7-$8, where it ought to be at this point. Both views imply that there is a deliberate conspiracy going on that involves the manipulation of XRP’s price. Aljarrah and Willie maintain that this is deliberate so that these powerful financial institutions can buy it cheaply before it gains adoption in the traditional finance space. “If the U.S. dollar is overextended and liquidity is strained as a result, XRP is the alternative source and bridge that provides liquidity for institutions,” Aljarrah wrote. The Black Swan Capitalist founder believes XRP could serve as a “bridge currency” that supplies liquidity for global transactions when the U.S. fiat currency faces stress. XRP…
Share
BitcoinEthereumNews2025/09/21 04:16
Top 5 News This Week: Senators vs. Chinese embassy; Rodrigo Duterte and ICC

Top 5 News This Week: Senators vs. Chinese embassy; Rodrigo Duterte and ICC

The Philippines' top news stories from January 25 to 31, 2026
Share
Rappler2026/01/31 20:00